DSS, Inc. (DSS) 股票分析
周期性消费DSS, Inc.
$0.53
+$0.02 (+4.16%)
最后更新: 2026年5月26日
价格走势
暂无价格数据
分析
公司概述
DSS, Inc. operates as a diversified enterprise within the United States, engaging in product packaging, biotechnology, commercial lending, securities and investment management, and direct marketing businesses. The company specifically manufactures, markets, and sells mailers, photo sleeves, custom folding cartons, and 3-dimensional direct mail solutions. This business model places the entity within the Consumer Cyclical sector, specifically the Packaging & Containers industry, where performance is often tied to discretionary consumer spending and broader economic cycles. With a market capitalization of $8.79M and annual revenue of $20.76M, the company operates on a small-cap scale. The market cap figure indicates that the company is a micro-cap entity with limited market influence, while the revenue level suggests a niche operational footprint that relies on specialized manufacturing capabilities rather than broad market dominance.
财务健康
The company reported revenue of $20.76M over the trailing twelve months, yet generated a net income of -$23,929,000 and an EBITDA of -$11,544,000. The substantial gap between the positive revenue and the negative net income reveals a deeply distressed cost structure where expenses significantly exceed gross proceeds, likely driven by the negative gross margin environment. Despite the reported net losses, the company reports a free cash flow of $43.30M, which suggests a potential discrepancy in accrual accounting or significant non-cash charges, providing a degree of operational cash liquidity that contrasts with the bottom-line losses. The company holds cash reserves of $8.91M but carries total debt of $43.06M, resulting in a debt-to-equity ratio of 494.14. This leverage ratio indicates an extremely high level of financial leverage and a balance sheet that is aggressively financed with debt relative to equity. The current ratio stands at 0.30, indicating that current assets are less than one-third of current liabilities, which signals severe short-term liquidity constraints and potential difficulty in meeting immediate obligations without refinancing. Furthermore, the Return on Equity is -132.7% and the Return on Assets is -10.4%, metrics that reveal management is currently destroying shareholder and asset value rather than generating returns on the capital deployed.
估值评估
The trailing twelve-month P/E ratio is listed as N/A due to the lack of earnings, while the forward P/E is calculated at -1.10. The negative forward P/E implies that expected future earnings are also negative, making traditional earnings-based valuation multiples inapplicable for assessing growth potential. The price-to-book ratio is -9.57, indicating that the market values the company at a significant discount to its book value, a common characteristic for distressed firms or those with impaired assets. Additionally, the price-to-sales ratio is 0.42 and the EV/EBITDA is -4.55; these alternative metrics suggest that valuation is being derived primarily from sales multiples given the absence of profitability, though the negative EV/EBITDA reinforces the earnings deficit. The stock has traded between a 52-week low of $0.72 and a 52-week high of $1.90. Given the current trading context, the price sits below the 52-week high, reflecting the market's skepticism regarding the company's ability to turn its operations profitable in the near term. The beta is 1.27, meaning the stock exhibits higher volatility than the broader market, amplifying price swings in response to sector-specific or macroeconomic events.
Growth & Income
Revenue growth year-over-year is -23.8%, while earnings growth is N/A due to the negative earnings baseline. The contraction in revenue indicates a shrinking top line, and without positive earnings, the concept of earnings growth is mathematically undefined until profitability is restored. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests all available cash flows, including the reported free cash flow, back into the business rather than distributing income to shareholders. This reinvestment strategy is critical for a firm with negative operating margins, as it attempts to fund operations and debt servicing internally without external equity issuance. The overall growth and income profile is characterized by negative revenue expansion and a complete lack of income distribution, highlighting a capital preservation phase rather than a growth or income generation phase for investors.
同行比较
DSS, Inc. (DSS) 在包装与容器行业运营。以下是其与市值最接近的同行的比较:
| 公司 | 代码 | 市值 | 市盈率 |
|---|---|---|---|
| DSS, Inc. | DSS | $5.28M | N/A |
| Smurfit Westrock Plc | SW | $20.56B | 54.4 |
| Packaging Corporation of America | PKG | $19.24B | 26.2 |
| Amcor plc | AMCR | $18.01B | 31.2 |
包装与容器行业平均市盈率为23.9倍。DSS, Inc.的市盈率为N/A。
本分析由AI生成,仅供参考,不构成投资建议。数据可能存在延迟或不准确。在做出投资决策之前,请务必进行自己的研究并咨询合格的财务顾问。
相关包装与容器股票
Smurfit Westrock Plc
$20.56B
PKGPackaging Corporation of America
$19.24B
AMCRAmcor plc
$18.01B
IPInternational Paper Company
$16.92B
BALLBall Corporation
$15.06B
AVYAvery Dennison Corporation
$12.22B
周期性消费热门股票
Amazon.com, Inc.
$3.76T
AMZNAmazon.com, Inc.
$2.85T
TSLA.TOTesla, Inc.
$2.13T
TSLATesla, Inc.
$1.63T
BABAAlibaba Group Holding Limited
$310.62B
关于DSS, Inc.
DSS, Inc. operates in the product packaging, biotechnology, commercial lending, securities and investment management, and direct marketing businesses in the United States. The company manufactures, markets, and sells mailers, photo sleeves, custom folding cartons, and 3-dimensional direct mail solutions; and markets and distributes nutritional and personal care products. It invests in or acquires companies in the biohealth and biomedical fields, including businesses that focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases; and develops open-air defense initiatives for air-borne infectious diseases comprising tuberculosis and influenza. In addition, the company focuses on acquiring equity positions in undervalued commercial banks, bank holding companies, and nonbanking licensed financial companies; and companies engages in nonbanking activities related to banking, such as loan syndication, mortgage banking, trust and escrow, banking technology, loan servicing, equipment leasing, problem asset management, special purpose acquisition company consulting, and advisory capital raising services. Further, the company provides securities and investment management services; and operates a real estate investment trust for acquiring hospitals and other acute or post-acute care centers. Additionally, it develops and acquires assets and investments in the securities trading and funds management arena, as well as lists and operates as a digital asset on secondary market. The company was formerly known as Document Security Systems, Inc. and changed its name to DSS, Inc. in September 2021. DSS, Inc. was incorporated in 1984 and is headquartered in West Henrietta, New York.
公司简介以英文显示。
访问官网 →